Publicaciones en colaboración con investigadores/as de Hospital del Mar (59)

2023

  1. Phase Ib study of talimogene laherparepvec in combination with atezolizumab in patients with triple negative breast cancer and colorectal cancer with liver metastases

    ESMO Open, Vol. 8, Núm. 2

2022

  1. Disinfection By-Products in Drinking Water and Bladder Cancer: Evaluation of Risk Modification by Common Genetic Polymorphisms in Two Case-Control Studies

    Environmental health perspectives, Vol. 130, Núm. 5, pp. 57006

  2. Soluble AXL is a novel blood marker for early detection of pancreatic ductal adenocarcinoma and differential diagnosis from chronic pancreatitis

    eBioMedicine, Vol. 75

  3. Upfront primary tumour resection and survival in synchronous metastatic colorectal cancer according to primary tumour location and RAS status: Pooled analysis of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

    European Journal of Surgical Oncology, Vol. 48, Núm. 5, pp. 1123-1132

2021

  1. A multilayered post-GWAS assessment on genetic susceptibility to pancreatic cancer

    Genome Medicine, Vol. 13, Núm. 1

  2. Deciphering the complex interplay between pancreatic cancer, diabetes mellitus subtypes and obesity/BMI through causal inference and mediation analyses

    Gut, Vol. 70, Núm. 2, pp. 319-329

2020

  1. Diesel exhaust and bladder cancer risk by pathologic stage and grade subtypes

    Environment International, Vol. 135

  2. Pancreatic Cancer Risk in Relation to Lifetime Smoking Patterns, Tobacco Type, and Dose-Response Relationships

    Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, Vol. 29, Núm. 5, pp. 1009-1018

2019

  1. Ambient air pollution and incident bladder cancer risk: Updated analysis of the Spanish Bladder Cancer Study

    International Journal of Cancer, Vol. 145, Núm. 4, pp. 894-900

  2. Author's reply to: Air pollution and incident bladder cancer: A risk assessment

    International Journal of Cancer

  3. Pancreatic cancer and autoimmune diseases: An association sustained by computational and epidemiological case–control approaches

    International Journal of Cancer, Vol. 144, Núm. 7, pp. 1540-1549

  4. Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy

    Annals of Oncology, Vol. 30, Núm. 3, pp. 439-446

2018

  1. Endothelial cell activation on 3D-matrices derived from PDGF-BB-stimulated fibroblasts is mediated by Snail1

    Oncogenesis, Vol. 7, Núm. 9

  2. Genotype-based selection of treatment of patients with advanced colorectal cancer (SETICC): A pharmacogenetic-based randomized phase II trial

    Annals of Oncology, Vol. 29, Núm. 2, pp. 439-444

  3. Increased plasma levels of galectin-1 in pancreatic cancer: Potential use as biomarker

    Oncotarget, Vol. 9, Núm. 68, pp. 32984-32996

  4. Risk of pancreatic cancer associated with family history of cancer and other medical conditions by accounting for smoking among relatives

    International Journal of Epidemiology, Vol. 47, Núm. 2, pp. 473-483

2017

  1. Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain

    Clinical and Translational Oncology, Vol. 19, Núm. 6, pp. 667-681

  2. Reduced risk of pancreatic cancer associated with asthma and nasal allergies

    Gut, Vol. 66, Núm. 2, pp. 314-322

2016

  1. Identification of a novel susceptibility locus at 13q34 and refinement of the 20p12.2 region as a multi-signal locus associated with bladder cancer risk in individuals of european ancestry

    Human Molecular Genetics, Vol. 25, Núm. 6, pp. 1203-1214

  2. Prediction of non-muscle invasive bladder cancer outcomes assessed by innovative multimarker prognostic models

    BMC Cancer, Vol. 16, Núm. 1